Monoclonal antibodies in solid tumours: Approaches to therapy with emphasis on gynaecological cancer

Medical Oncology

Volumn 15, Issue 4, 1998, Pages 212-221

  Fleckenstein, G ^a   Osmers, R ^a   Puchta, J ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Active and passive specific immunotherapy; Bispecific monoclonal antibodies; Chemoimmunoconjugates; Monoclonal antibodies; Radioimmunoconjugates; Solid tumours

Indexed keywords

ALPHA INTERFERON; ANTIBODY CONJUGATE; ANTIIDIOTYPIC ANTIBODY; EDRECOLOMAB; INDIUM 111; INTERLEUKIN 2; IODINE 123; IODINE 131; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY OC 125; ONCOSCINT; RADIOISOTOPE; TECHNETIUM 99M; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; GYNECOLOGIC CANCER; HUMAN; IMMUNOSCINTIGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; OVARY CANCER; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR;

EID: 0032457328     PISSN: 07360118     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02787203     Document Type: Review

References (65)

1. Mallmann P. Immuntherapie in der gynäkologischen Onkologie. Geburtsh Frauenkeilk 1994; 54: 137-139.
2. MacLean G, Reddish MA, Bowen-Yacyshyn MB, Poppema S, Longenecker BM. Active specific immunotherapy against adenocarcinomas. Cancer Invest 1994; 12: 46-56.
3. Gramatzki M, Valerius T. Antikörper als spezifische Tumortherapeutika. Wunschtraum oder Realität? Internist 1997; 38: 1055-1062.
4. Ehrlich P. On immunity with special reference to cell life. Proc R Soc Lond 1900; 66: 424-448.
5. Kruit WHJ, Stoter G. The role of adoptive immunotherapy in solid cancers. Neth J Med 1997; 50: 47-68.
6. Köhler G, Milstein C. Continuous cultures of fused cells producing antibodies to predefined specificity. Nature 1975; 256: 495-497.
7. Oettger HF, Hellström KE. Principles of immunology: tumor immunology. In: Holland, Frei (eds). Cancer Med Lea and Febiger: Philadelphia, 1982, p 1029.
8. Schirrmacher V. Tumoren: Entstehung, Metastasierung und immunologische Abwehrmechanismen. In: Gemsa D, Kalden JR, Resch K (eds). Immunologie. Thieme: Stuttgart/New York 1991, p 185.
9. Steplewski Z. Advances and outlooks for immunotherapy of cancer. Hybridoma 1993; 12: 493-500.
10. Ahlert T, Bastert G, Schirrmacher V. Mamma- und Ovarial-Karzinom mit autologen, virusmodifizierten Tumorzellen, aktiv-spezifische Immuntherapie (ASI): Theorie, Praxis, Perspektiven. Therapiewoche Gynäkologie 1989; 2: 359-364.
11. Wagner U et al. Clinical courses of patients with ovarian carcinomas after the induction of anti-idiotypic antibodies against a tumour-associated antigen - an approach to immunotherapy of advanced ovarian cancer. Tumor Diagnostik Ther 1990; 11: 1-4.
12. Osmers RGW, Rybicki T, Meden H, Kuhn W. Does an immunoscintigraphy with OC 125 affect the prognosis of ovarian cancer? Eur J Gynaec Oncol 1997; 177-182.
13. Grimm EA, Mazumdar A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823-1841.
14. Canirell DA, Smith KA. The interleukin-2 T-cell system: a new cell growth model. Science 1984; 224: 1312-1316.
15. Gemlo BT, Palladino MA, Jaffe HS, Espevik TP, Rayner AA. Circulating cytokines in patients with 'metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 1988; 48: 5864-5867.
16. Rosenberg SA et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897.
17. Rosenberg SA et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-485.
18. Buter J et al. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2. Semin Oncol 1993; 20: 16-21.
19. Baron S et al. The interferons. Mechanisms of action and clinical applications. J Am Med Assoc 1991; 266: 1375-1383.
20. Quesada JR et al. Antitumor activity of recombinant-derived interferon-a in metastatic renal cell carcinoma, J Clin Oncol 1985; 3: 1522-1528.
21. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102: 127-141.
22. Mallmann P. Autologous tumor cell vaccination and lymphokine-activated tumour-infiltrating lymphocytes (LAK-TILs). Hybridoma 1993; 12: 559-564.
23. Coons T. Monoclonal antibodies: the promise and the reality. Radiol Technol 1995; 67: 39-60.
24. Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-327.
25. Marks C, Marks JD. Phage libraries - a new route to clinically useful antibodies. N Engl J Med 1996; 335: 730-733.
26. Yao Z et al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal antibodies through an avidin chase. J Nucl Med 1995; 36: 837-841.
27. Chatal JF et al. Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?. Eur J Nucl Med 1992; 19: 205-213.
28. Bast RC et al. Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981; 68: 1331-1337.
29. Bast RC et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. New Engl J Med 1983; 309: 883-887.
30. Gitsch E, Pateisky N. Radioimmunoszintigraphie beim Ovariaikarzinom: Theoretische Grundlagen und klinischen Erfahrungen. Arch Gynecol Obstet 1987; 242: 365-370.
31. Munz DL. Immunszintigraphie mit monoklonalen Antikörpern. Dtsch med Wschr 1987; 112: 649-654.
32. Koprowski H, Herlyn D, Lubeck M, Defreitas E, Sears F. Human anti-idiotype antibodies in cancer patients: Is the modulation of the immune response beneficial for the patient?. Proc Natl Acad Sci USA 1984; 81: 216-219.
33. Stramignoni D, Bowen R, Atkinson BR, Schlom J. Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomas. Int J Cancer 1983; 31: 543-552.
34. Rodwell JD et al. Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. Proc Natl Acad Sci USA 1986; 83: 2632-2636.
35. Maguiere RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian and prostatic cancer. Cancer 1993; 72: 3453-3462.
36. Nabi HA, Doerr RJ, Balu D, Rogan L, Farrell EL, Evans NH. Gamma probe assisted ex vivo detection of small lymph node metastases following the administration of indium 111-labeled monoclonal antibodies to colorectal cancers. J Nucl Med 1993; 34: 1818-1822.
37. Imai K, Hareyama M, Makiguchi Y, Matsumoto H, Hinoda Y. Monoclonal antibody-conjugated immunotherapy of cancer. Intern Rev Immunol 1997; 14: 213-227.
38. Gramatzki M et al. Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2-responsiveness. Leukemia 1995; 9: 382-390.
39. Baum W et al. Therapy with monoclonal antibody TH-69 is highly effective for xenografted human T-cell ALL. Br J Haematol 1996; 95: 327-338.
40. Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497-1515.
41. Grossbard ML, Press OW, Appelbaum FR, Bernstein ID, Nadler LM. Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 1992; 80: 863-878.
42. Herlyn D, Lubeck M, Sears H, Koprowski H. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody. J Immunol Methods 1985; 85: 27-39.
43. Jurcic JG, Scheinberg DA, Houghton AN. Monoclonal antibody therapy of cancer. Cancer Chemotherapy and Biological Response Modifiers Annual 1994; 15: 152-175.
44. de Santes K et al. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. Cancer Res 1992; 52: 1916-1923.
45. Baselga J et al. Phase II study of weekly intravenous recombinant humanized anti-p 185HER-2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-744.
46. Riethmüller G et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 1177-1183.
47. Courtenay-Luce NS et al. Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies . Lancet 1988; 15: 894-896.
48. Wagner U. Antitumor antibodies for immunotherapy of ovarian carcinomas.. Hybridoma 1993; 12: 521-528.
49. Deo YM, Graziano RF, Repp R, Van de Winkel JGJ. Clinical significance of IgG receptors and FcyR-directed immunotherapies. Immunol Today 1997; 18: 127-135.
50. Valone FH et al. Phase 1a/1b trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogen Her-2/neu. J Clin Oncol 1995; 13: 2281-2292.
51. Repp R et al. G-CSF stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to FryR1 and to HER-2/neu (MDX 210). J Hematother 1995; 4: 415-421.
52. Canevari S et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87: 1463-1469.
53. Weiner LM et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 1993; 53: 94-100.
54. Vallera DA. Immunotoxins: will their clinical promise be fulfilled?. Blood 1994; 83: 309-317.
55. Wilder RB, DeNardo GL, DeNardo SJ. Radioimmuno-therapy: recent results and future directions. J Clin Oncol 1996; 14: 1383-1400.
56. Schlom J et al. Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates. Cancer Res 1992; 52: 1067-1072.
57. Rao DV, Howell RW. Time-dose-fractionation in radio-immunotherapy: implications for selecting radionuclids. J Nucl Med 1993; 34: 1801-1810.
58. 131I-labeled monoclonal antibody E48 IgG. Br J Cancer 1992; 66: 496-502.
59. Bardiès M et al. Dosimetric estimations from uptake and retention kinetics of indium-111-labeled OC125 antibody in ovarian carcinoma (OC) multicell spheroids. J Nucl Med 1991; 32: 997 (abstr).
60. Koch B et al. In vitro activity of immunoconjugates between cisplatinum and monoclonal antibodies. Antibody Immunocon Radiopharm 1991; 4: 121-132.
61. Trail PA et al. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models. Cancer Res 1992; 52: 5693-5700.
62. Trail PA et al. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates. Cancer Res 1997; 57: 100-105.
63. Pegram M et al. Phase II study of intravenous recombinant humanised anti-p185 HER-2/neu monoclonal antibody (rHu Mab HER-2) plus cisplatinum in patients with HER-2/neu overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1995; 14: 106a.
64. Scott AM, Welt S. Antibody-based immunological therapies. Current opinion in immunology. Curr Sci 1997; 9: 717-722.
65. Ben-Efraim S. Cancer immunotherapy: hopes and pitfalls: a review. Anticancer Res 1996; 16: 3235-3240.